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ABSTRACT
Introduction: The objective of this study was to
estimate the relative efficacy and safety of
fixed-dose combination aclidinium/formoterol
400/12 lg twice daily compared to tiotropium
18 lg once daily in adult patients with
moderate-to-severe chronic obstructive
pulmonary disease (COPD).
Methods: A systematic literature review
performed in March 2014, using a predefined
search strategy in MEDLINE, EMBASE and
Cochrane Library, identified 17 randomized
placebo-controlled trials, (tiotropium n = 15;
aclidinium/formoterol n = 2). Outcomes of
interest were: bronchodilation (peak and
trough forced expiratory volume in 1 s (FEV1)),
COPD symptoms [Transition Dyspnea Index
(TDI) focal score and % of responders ([1 unit
improvement)] and Health Related Quality of
Life (HRQoL) [St. George’s Respiratory
Questionnaire (SGRQ) total score and %
responders ([4 unit improvement)], % of
patients with C1 exacerbations, adverse events
(AE), serious adverse events (SAE),
hospitalization and mortality, all at 24 weeks.
In the absence of head-to-head trials between
aclidinium/formoterol and tiotropium, a
Bayesian indirect treatment comparison (ITC)
was used with placebo as common control.
Results: Regarding bronchodilation,
aclidinium/formoterol was found to be more
efficacious than tiotropium at peak FEV1, with
mean difference in change from baseline
(DCFB) 143 mL [95% credible interval (CrI):
112, 174] and at trough FEV1 [DCFB 26 mL
(95% CrI -2, 55)]. Aclidinium/formoterol is
expected to be more efficacious than tiotropium
in improving dyspnea symptoms measured by
TDI [DCFB 0.54 points (95% CrI 0.09, 0.99);
odds ratio (OR) of responders 1.51 (95% CrI
1.11, 2.06)]. SGRQ results are comparable for
aclidinium/formoterol versus tiotropium [DCFB
-0.52 (95% CrI -2.21, 1.17); OR of responders
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1.16 (95% CrI 0.47, 2.87)]. The ITC results
suggest similar safety profiles regarding AEs,
SAEs and hospitalization.
Conclusion: Based on the ITC,
aclidinium/formoterol is expected to be more
efficacious than tiotropium in terms of lung
function and symptom control while providing
comparable HRQoL results and safety profile.
Funding: AstraZeneca.
Keywords: Aclidinium; Formoterol; Indirect
treatment comparison; Literature review;
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INTRODUCTION
Chronic obstructive pulmonary disease (COPD)
is a disorder characterized by the progressive
development of airway obstruction, which
manifests as an accelerated decline in lung
function, with symptoms such as breathlessness
on physical exertion, deteriorating health status
and exacerbations [1].
Currently COPD is the fourth leading cause
of death globally [2], a major cause of morbidity
and mortality, projected to become the world’s
third leading cause of mortality by 2020 [3].
Characterized by progressive airflow limitation,
COPD also has a major economic impact [4].
According to the COPD Guidelines from
2011, which were updated in 2015, it is
recommended to combine two long-acting
bronchodilators in moderate-to-severe COPD
patient groups [5]. The combination of two
bronchodilators with different mechanisms of
action, such as long-acting muscarinic
antagonists (LAMAs) and long-acting
b2-agonists (LABAs), are a successful treatment
option for patients with COPD. Compared to
single bronchodilators, the combination of
LAMAs and LABAs demonstrates significant
improvements in lung function without
increasing the risk for adverse events [5–8].
The use of fixed-dose combinations (FDCs) of
LABAs and LAMAs provide the opportunity to
improve the accessibility and conformity
compared to separate inhalers. Also, the dose
of each substance used in the combination can
be enhanced. An objection related to the
development of an FDC is the arrangement of
improved bronchodilation over monotherapy
segments, while adjusting the associated
adverse effects with efficacy [9]. The safety and
efficacy profiles of both LAMAs and LABAs are
well accepted. However, it is important to
recognize both the similarities and differences
in both efficacy and safety, when combining
two substances.
A new LABA/LAMA FDC,
aclidinium/formoterol 400/12 lg twice-daily
(BD), has recently been introduced in the
management of COPD. The FDC,
aclidinium/formoterol, is compared to placebo
and aclidinium and formoterol as
monotherapies in two pivotal, randomized,
placebo-controlled studies [ACLIFORM
(ClinicalTrials.gov identifier NCT01462942)
and AUGMENT (Clinicaltrials.gov identifier
NCT01437397)] [10, 11]. Results from both
studies show a significant improvement in
24 h symptom control compared with placebo
and aclidinium and formoterol monotherapies.
Furthermore, in the aclidinium/formoterol
group, the frequency of exacerbations is also
reduced compared to placebo [6].
Tiotropium 18 lg is a once-daily treatment
and has been the first and most widely
prescribed LAMA for COPD, considered as the
standard of care in many countries [12]. Based
on the outcomes of the AUGMENT and
ACLIFORM studies, it is expected that an FDC
of aclidinium/formoterol will be more efficient
on key COPD outcomes, compared to LAMA
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monotherapies. As there are no published direct
head-to-head comparisons on the clinical
efficacy and safety between FDC
aclidinium/formoterol and tiotropium,
alternative methodologies need to be
employed to inform health-care practitioners.
For this reason, a systematic literature review
and Bayesian indirect treatment comparison
(ITC) were undertaken to assess the relative
efficacy and safety of aclidinium/formoterol
400/12 lg BD versus tiotropium 18 lg once




A systematic literature review was performed to
identify randomized placebo-controlled trials
(RCTs) reporting the safety and efficacy of
aclidinium/formoterol 400/12 lg and
tiotropium 18 lg compared to each other or
placebo. Using a predefined strategy,
MEDLINE, MEDLINE in-process and
EMBASE databases were searched
simultaneously through the OVID platform,
while the Cochrane Central Register of
Controlled Trials was searched separately. The
American Thoracic Society International
Conference (2013) and European Respiratory
Society International Congress (2013) were
hand-searched for relevant abstracts. In
addition, the search was also performed in
ClinicalTrials.gov website. The searches were
performed on March 24, 2014, for studies in
English language with a time restriction from
the year 1989 to March 2014. The predefined
search strategies used were tailored for each
database and are presented in Supplementary
Table 1. This article is based on previously
conducted studies and does not involve any
new studies of human or animal subjects
performed by any of the authors.
Study Selection Process
The relevance of each citation identified was
assessed according to predefined abstract
selection criteria (Supplementary Table S2).
First, titles and abstracts were screened for
eligibility, and then full texts of the selected
articles were assessed by one researcher and
checked against the original study by another.
Those that met the inclusion criteria were
included for data extraction.
The studies of interest were RCTs with
duration of 22–26 weeks, including adults with
moderate-to-severe COPD, reporting on
aclidinium/formoterol 400/12 lg BD (using
the Genuair device [AstraZeneca AB,
So¨derta¨lje, Sweden]) or tiotropium 18 lg OD
(using the Handihaler device [Boehringer
Ingelheim, Ridgefield, USA]) compared with
each other or placebo. The efficacy outcomes
of interest were: trough forced expiratory
volume in 1 s (FEV1) (pre-bronchodilatory),
peak FEV1 (post-bronchodilatory), St. George’s
Respiratory Questionnaire (SGRQ) score,
Transition Dyspnea Index (TDI) focal score
and the % of patients with C1 exacerbations.
The safety outcomes of interest were: adverse
events, serious adverse events, hospitalization
and mortality. In all cases, outcomes reported in
the range of 22–26 weeks were grouped as
24 weeks.
Data Abstraction and Quality Assessment
For the studies identified that met the inclusion
criteria, details were extracted on population
characteristics, interventions, outcomes and the
study design of interest at 24 weeks
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(22–26 weeks) (Tables 1, 2, Supplementary
Table S5, Supplementary Table S6). Data
abstraction was performed by one researcher
and verified against the original study
publication by another. Data of interest
presented in graphs were extracted using
DigitizeIT version 4.1 software (DigitizeIT,
Braunschweig, Germany).
For continuous outcomes, the change from
baseline (CFB) and the associated sampling
variance were extracted or calculated based on
the available data. For dichotomous outcomes,
the number of patients experiencing an event
was extracted or estimated based on the
reported percentages and intention to treat
population, and the total patient-years of
follow-up were calculated.
The validity of each trial used in the ITC was
assessed using the National Institute of Health
and Clinical Excellence (NICE) checklist. The
results of this assessment were not explicitly
used in the ITC, but serve as additional
information to determine the quality of the
evidence base when interpreting the results
(Supplementary Table S3).
Data Synthesis: Indirect Treatment
Comparison
The existence of a connection between the
treatments of interest via a common control
(placebo), as well as the study design and
patient characteristics of the identified studies,
was used to assess the feasibility of a valid ITC
[13]. Subsequently, the identified evidence was
used to perform an ITC within a Bayesian
framework to simultaneously synthesize the
results of the included studies and obtain
relative treatment effects [14, 15]. A linear
model with normal likelihood distribution was
used for continuous outcomes, and a Poisson
likelihood with a log link for the dichotomous
outcomes [16]. Flat (non-informative) prior
distributions, normal with zero mean and
variance of 10,000, were assumed for the
relative treatment effects of all outcomes. A
uniform distribution with range 0–5 was used as
the prior of the between-study standard
deviation.
For each outcome, a fixed and a random
effects model was evaluated. The goodness of fit
of each model to the data was assessed using the
deviance information criterion [17]. The
posterior densities were estimated using the
Markov chain Monte Carlo (MCMC)
simulations based on 80,000 iterations on
three chains, with a burn-in of 20,000
iterations. Convergence assessment was based
on visual inspection of trace plots and accuracy
of the posterior estimates using the Monte Carlo
error for each parameter. WinBUGS 1.4.3 (MRC
Biostatistics Unit, Cambridge, UK) statistical
software was used for the analyses and the
models were based on those defined by Dias
et al. [18]. The posterior distributions were
summarized with the median to reflect the
most likely value of the estimate, and the
2.5th and 97.5th percentile to capture the 95%
credible interval (CrI). For each end point, the
probability that each treatment was better than
a certain comparator was established.
RESULTS
Search and Selection Results
After searching, a total of 2401 abstracts from
the databases and 88 clinical trials from
ClinicalTrials.gov were identified (Fig. 1).
Following the abstracts and full-text
publication screening stages, 17 full-text
publications [8, 12, 19–33] were identified and
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3 clinical study reports [34–36] were provided
by AstraZeneca. In total, the evidence base
comprised 15 different studies; 13 studies [8,
12, 19–33, 36] compared tiotropium 18 lg to
placebo (14,697 patients) and two studies [34,
35] compared aclidinium/formoterol 400/12 lg
to placebo (1246 patients).
Study Characteristics
An overview of the study characteristics is
presented in Table 1. All studies were
multicenter, placebo-controlled RCTs. Twelve
studies [8, 12, 19–22, 24–28, 30, 31, 33, 36] were
double-blind and three [23, 29, 32] included
tiotropium as an open-label arm. The included
studies varied in terms of the number of
patients randomized to each treatment,
ranging from 117 [31] to 3006 [12, 22]. The
trial duration varied from 96 weeks [33] to
24 weeks [23–27, 34, 35]. The use of ICS
(inhaled corticosteroids) as a background
treatment was allowed in all studies and
patients were permitted a short-acting
beta-agonist as rescue medication (salbutamol
or albuterol). The studies were of comparable
quality, according to the results of the
assessment using NICE questionnaire
Fig. 1 Flowchart of the study selection process. ATS American Thoracic Society, CSR clinical study report, ERS European
Respiratory Society
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(Supplementary Table S3). In general, the
method of randomization and concealment of
treatment allocation was well reported.
Patient Characteristics
An overview of the main patient characteristics is
provided in Table 2. The enrolled patients were
adults with a COPD diagnosis. The studies
included a predominantly male population,
ranging from 50% [35] to 99% [24], while in
three studies [21, 24, 31] more than 80% of the
included patients were male in both arms. The
patients’ average age across all the studies was
similar (range 63–68 years). Overall, spirometry
measures were fairly consistent at baseline.
According to the inclusion criteria, most studies
required an FEV1/forced vital capacity (FVC) of
less than or equal to 0.70 and an FEV1% predicted
range between 30% and 80%. The mean FEV1%
predicted at baseline ranged between 35.6% and
56.4%. FEV1 at baseline ranged from 0.96 liter
(L) to 1.55 L. The FEV1/FVC at baseline was
reported to be between 41.3% and 55.3%. Across
all the included studies, thepercentageofpatients
per arm that used ICS at baseline ranged between
7% and 71%. The percentage was lower in both
aclidinium/formoterol trials (7% to 9% for
LAC-MD-31 and 19–22% for M/40464/30R) than
in the other studies (35–71%). Furthermore, all
studies included patients who were current or
ex-smokers. In studies where the percentage of
current smokerswas reported, it ranged from40%
to 53%. Six studies (reported in 7 publications:
[23, 25–29, 31]) did not report the percentage of
current smokers. Themean number of pack-years
ranged from 35.0 to 69.4 years.
Indirect Treatment Comparison
Despite some differences identified across the
studies in terms of study design and patient
characteristics, the 15 RCTs (reported in 20
publications) are considered to be broadly
comparable and the ITC was feasible [13]. The
diagram of the trials included in the ITC is
shown in Fig. 2.
Efficacy Outcomes
Individual study results for efficacy outcomes
are presented in Supplementary Table S5, where
data not reported but estimated are denoted by
an asterisk. The results of the ITC analysis are
presented in Table 3. Regarding lung function,
for both outcomes considered in this study, i.e.,
peak and trough FEV1, aclidinium/formoterol
400/12 lg appeared to be more efficacious
compared to tiotropium 18 lg at 24 weeks.
Regarding health-related quality of life, as
measured by SGRQ total score, the individual
study results for aclidinium/formoterol
demonstrate high variation between the
M/40464/30R and LAC-MD-31 studies. The
cause of this variation is unknown and cannot
be explained by differences in study design or
patient characteristics. The heterogeneity is
reflected in the results of the ITC by means of
wide credible intervals with a difference in CFB
of -0.52 (95% CrI -2.21, 1.17). Similarly, for
the % of responders (patients with [4 units
reduction), the relative effect is heterogeneous
with variation between M/40464/30R and
LAC-MD-31 studies with an odds ratio (OR)
1.16 [95% CrI (0.47, 2.87)]. Due to this high
variation, the results should be interpreted with
Fig. 2 Network of studies included in the indirect
treatment comparison
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caution; aclidinium/formoterol appeared to be
comparable to tiotropium for both SGRQ total
score and % responders.
Aclidinium/formoterol was more efficacious
than tiotropium in improving breathlessness
measured by TDI and % responders (i.e.,
patients with[1 point increase from baseline).
With regard to the percentage of patients
with at least one exacerbation,
aclidinium/formoterol was likely to be better
compared to placebo with OR of 0.78 [95% CrI
(0.56, 1.08)] and comparable to tiotropium with
OR 1.03 (95% CrI [0.73, 1.47]). For this
outcome, the time period of 24 weeks is
relatively short, as the results are heavily
dependent on the recent history of the
patients recruited (e.g., if they had an
exacerbation within the last months before
recruitment, see inclusion/exclusion criteria in
Table 1). Furthermore, the percentage of
patients with at least one exacerbation in the
placebo arm is almost 3.5 times higher in
Donohue et al. 2002 and 2003 [26, 27] (45.8%)
than in M/40464/30R (13.4%) [34], suggesting
differences in COPD severity, in
exacerbation-related study inclusion criteria or
in the way the exacerbations were defined/
reported. For these reasons, the results of the
ITC shall be interpreted with caution.
Safety Outcomes
For the safety outcomes, the individual study
results are presented as: number of patients with
an event (n); number of patients included in the
analysis (N); and proportion of patients with an
eventper treatmentarm(SupplementaryTableS6).
Compared to placebo,
aclidinium/formoterol [OR 1.19; 95% CrI
(0.95, 1.49)], and tiotropium [OR 1.03; 95%
CrI (0.85, 1.24)] resulted in a mean OR above 1,
suggesting an advantage for placebo, although
Table 3 ITC results for aclidinium/formoterol versus tiotropium at 24 weeks
Outcome Mean 95% CrI Prob. better (%)
Efﬁcacy
Peak FEV1 (DCFB, mL) 143.2 (112.00, 174.50) [99
Trough FEV1 (DCFB, mL) 26.21 (-2.31, 54.72) 96
SGRQ total score (DCFB, units) -0.52 (-2.21, 1.17) 73
SGRQ responders (OR, C4 units improvement) 1.16 (0.47, 2.87) 68
TDI focal score (difference vs. comparator) 0.54 (0.09, 0.99) [99
TDI responders (OR, C1 points improvement) 1.51 (1.11, 2.06) [99
Patients with at least 1 exacerbation (OR) 1.03 (0.73, 1.47) 43
Safety
Adverse events (OR) 1.16 (0.86, 1.55) 17
Serious adverse events (OR) 1.22 (0.71, 2.16) 24
Hospitalization 1.03 (0.37, 2.90) 48
CrI credible interval, DCFB difference in change from baseline, FEV1 forced expiratory volume in 1 s, mL milliliters, OR
odds ratio, Prob. better probability of aclidinium/formoterol being a better treatment than tiotropium for this outcome,
SGRQ St. George’s Research Questionnaire, TDI Transitional Dyspnea Index
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not a significant one as the CrI included 1 in all
cases. In both cases, the results of this analysis
should be interpreted with extreme caution,
first due to the limited number of studies, the
time of assessment (24 weeks is a rather short
period for safety outcomes) and potential
differences in the way this outcome is reported
in each study.
In the results of the ITC for serious adverse
events for active treatments compared to
placebo, the median OR for all active
treatments was above 1 suggesting an
advantage for placebo, but in all cases the
credible intervals included 1; thus, the
difference cannot be considered as significant.
In line with this in pairwise comparisons
between the active treatments, the CrI include
1 in all cases. Regarding AEs, the results of this
analysis should be interpreted with extreme
caution, due to the limited number of studies
and the time of assessment (24 weeks is a rather
short period for safety outcomes).
The results of the ITC regarding the
proportion of patients with hospitalization
within 24 weeks are uncertain for
aclidinium/formoterol versus placebo with an
OR 0.65 [95% CrI (0.22, 1.64)], mainly due to
the lack of data, while for tiotropium the OR
was 0.59 [95% CrI (0.46, 0.74)] versus placebo.
Similarly, aclidinium/formoterol was
comparable to tiotropium with OR 1.03 [95%
Crl (0.37, 2.90)], but with high uncertainty.
The ITC for mortality was not
(computationally) feasible, as the majority of
the studies reported zero events (deaths) which
lead the algorithm (MCMC) to numerical
overflow, even when applying a continuity
correction of 0.5. With such a large proportion
of trials with zero events, estimation of a
treatment effect and its variance becomes
practically impossible. The individual study
results for mortality are presented in
Supplementary Table S6.
DISCUSSION
Based on the results of the ITC,
aclidinium/formoterol is expected to be more
efficacious than tiotropium in terms of peak
FEV1, TDI focal score and TDI responders.
Regarding trough FEV1, aclidinium/formoterol
is expected to be favorable compared to
tiotropium. In all other efficacy and safety end
points, aclidinium/formoterol and tiotropium
are expected to result in similar (comparable)
outcomes. The analysis for mortality was not
feasible because the majority of the studies
reported zero events.
A few other studies compared LABA/LAMA
combinations versus tiotropium in a
head-to-head trial. Both the SHINE study
(ClinicalTrials.gov identifier, NCT01202188)
[8] and SPARK study (ClinicalTrials.gov
identifier, NCT01120691) [37] compared
QVA149 (indacaterol 110 mg/glycopyrronium
50 mg) to tiotropium. The SHINE study reports
comparable results to our study with superior
improvements in lung function for the QVA149
group compared to tiotropium. The safety
results are comparable to placebo and with no
additional safety signal compared to tiotropium
[8]. The SPARK study also shows similar results,
with a significant reduction in the rate of all
exacerbations, and a significant improvement
in trough FEV1 and health status favoring the
dual LABA/LAMA bronchodilator QVA149
versus tiotropium. Furthermore, no safety
differences between the dual LABA/LAMA
bronchodilator and tiotropium are found [37].
Decramer et al. [38] and Maleki-Yazdi et al. [39]
both compared umeclidinium plus vilanterol
versus tiotropium. Both studies report a
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significant improvement in lung function
compared to tiotropium, and no safety
differences are found between the groups.
It is challenging to demonstrate the
relevance of the end points on COPD studies
comparing combination therapy to
monotherapy. To determine the clinical
effectiveness, the minimum clinically
important difference (MCID) is often used to
acknowledge a clinically significant effect. This
measure is however focused on the comparison
of a monotherapy versus placebo. When
comparing a combination therapy to a
monotherapy, uncertainty has occurred if the
MCID is a valid measure, because the
differences in effects tend to be smaller since
both arms receive active therapy. Jones et al.
[40] discuss this issue and have introduced the
‘minimum worthwhile incremental advantage’
which can be used to describe the percentage of
patients experiencing improvement at or above
MCID when adding active treatment on top of
another active treatment or when comparing
two active treatments to each other [6, 40].
Furthermore, there are a number of other
potential limitations to this analysis. First, as for
any meta-analysis, inherent limitations are
related to the potential for within-study bias
and publication bias. Furthermore, there are
differences in the definitions of exacerbations
and in study methodology, populations that
could introduce bias. For example, across all the
included studies, the percentage of patients per
arm that used ICS at baseline ranged between
7% and 71%. The percentage was lower in both
aclidinium/formoterol trials (7–9% for
LAC-MD-31 and 19–22% for M/40464/30R)
than in the other studies (35–71%). Also, for
the SGRQ total score outcome, the CFB versus
placebo reported for aclidinium/formoterol
400/12 demonstrated high variation between
the M/40464/30R and LAC-MD-31 studies. The
cause of this variation is unknown and cannot
be explained by the study designs or patient
characteristics.
In addition, bias could be introduced due to
the imbalances in potential treatment effect
modifiers (e.g., FEV1 predicted at baseline) and
differences in the background medications. Due
to the lack of access to individual patient data
and the low number of studies (especially for
aclidinium/formoterol), it was not feasible to
further explore these differences.
Furthermore, it is considered complicated to
include safety in indirect comparisons, since
this is not a straightforward approach. However,
we decided to include safety next to efficacy
outcomes, since a benefit–risk assessment will
add important data about the intervention.
CONCLUSION
The results of this analysis suggest that
aclidinium/formoterol is more efficacious with
a similar safety profile compared to tiotropium.
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